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Abstract
Background and purpose: The effects of single-nucleotide polymorphisms
(SNPs) on the cognitive function of opioid-treated patients with cancer until
now have not been explored, but they could potentially be related to poor func-
tioning. This study aimed at identifying associations between SNPs of candidate
genes, high opioid dose, and cognitive dysfunction. Methods: Cross-sectional
multicenter study (European Pharmacogenetic Opioid Study, 2005–2008); 1586
patients; 113 SNPs from 41 genes. Inclusion criteria: cancer, age ≥18 year, opioid
treatment, and available genetic data. Cognitive assessment by Mini-Mental State
Examination (MMSE). Analyses: SNPs were rejected if violation of Hardy–Wein-
berg equilibrium (P < 0.0005), or minor allele frequency <5%; patients were
randomly divided into discovery sample (2/3 for screening) and validation sam-
ple (1/3 for confirmatory test); false discovery rate of 10% for determining asso-
ciations (Benjamini–Hochberg method). Co-dominant, dominant, and recessive
models were analyzed by Kruskal–Wallis and Mann–Whitney tests. Results: In
the co-dominant model significant associations (P < 0.05) between MMSE
scores and SNPs in the HTR3E, TACR1, and IL6 were observed in the discovery
sample, but the replication in the validation sample did not confirm it. Associa-
tions between MMSE scores among patients receiving ≥400 mg morphine equiv-
alent dose/day and SNPs in TNFRSF1B, TLR5, HTR2A, and ADRA2A were
observed, but they could not be confirmed in the validation sample. After cor-
rection for multiple testing, no SNPs were significant in the discovery sample.
Dominant and recessive models also did not confirm significant associations.
Conclusions: The findings did not support influence of those SNPs analyzed to
explain cognitive dysfunction in opioid-treated patients with cancer.
Introduction
Patients with advanced cancer develop very frequently a
wide range of symptoms, including cognitive dysfunction,
which interfere with their daily life, health status, progno-
sis, compliance to treatment, social interactions, and qual-
ity of life. Causes for development of cognitive alterations
are multiple and may be attributed to the cancer disease
itself, comorbidities, and treatments including opioid ther-
apy (Levine et al. 1978; Massie et al. 1983; Sjøgren 1997;
Bruera et al. 1992; Baumgartner 2004; Kurita and Pimenta
2008). Some causes may be reversible or manageable; how-
ever, the knowledge and scientific exploration regarding
this issue in patients with cancer is in its infancy.
Opioid treatment to manage cancer pain is the corner-
stone in clinical practice and these drugs are highly rec-
ommended by WHO (1996) for this purpose. However,
opioids have several adverse effects on the central nervous
ª 2016 The Authors. Brain and Behavior published by Wiley Periodicals, Inc.
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system and many of these effects are still unclear. Opioids
can interfere with acquirement, processing, storage, and
retrieval of information (Lawlor 2002). In addition to
altering cognitive processes associated with memory, they
can alter psychomotor function, mood, concentration,
and other mental capabilities (Kurita et al. 2009).
In the past, questions related to opioid effects on cog-
nition in patients with cancer did not represent a major
point of concern. In palliative care, a possible reason for
this was due to fast disease progression and short life
expectancy. However, recently, an increased attention
regarding cognitive functioning in palliative care as well
as during the entire cancer trajectory has been noticed,
although neuropsychological assessment of patients with
cancer is a relatively new research area still based on
rather limited scientific evidence. Thus, identification of
mental alterations, specially mild and subtle alterations,
are still frequently ignored and left undisclosed and trea-
ted (Inouye et al. 2001; Pisani et al. 2003).
We have formerly undertaken two studies in a multina-
tional sample of opioid-treated patients with cancer, in
which the cognitive effects of a wide range of variables
were investigated (Kurita et al. 2011, 2015). They demon-
strated that nearly 1/3 of opioid-treated patients with can-
cer presented possible or definite cognitive dysfunction
and several factors, including opioid dose, were associated
with the dysfunction (Kurita et al. 2011, 2015). Based on
these series of studies, we considered that genetic factors
could also be involved in the cognitive performance of
opioid-treated patients with cancer and decided to pro-
ceed with analyzing potential candidate genes in the sam-
ple investigated in the previously mentioned studies.
Literature on associations between cognitive dysfunc-
tion and genetic variation in opioid-treated patients with
cancer is practically nonexistent. In addition, knowledge
on genetic influence on some specific cognitive disorders
seems to be sparse (Flint 1999, 2001). Therefore, this
study aimed at analyzing associations between single-
nucleotide polymorphisms (SNPs) of candidate genes and
cognitive functioning in opioid-treated patients with can-
cer. Moreover, keeping in mind that high opioid doses
have previously been associated with cognitive dysfunc-
tion (Kurita et al. 2011, 2015), associations between SNPs
in patients treated with high opioid doses and cognitive
functioning were also investigated.
Methods
Design and sample
The sample analyzed in this study is derived from the
European Pharmacogenetic Opioid Study (EPOS), which
is a cross-sectional and multicenter investigation con-
ducted in 11 countries during 2005–2008 (Klepstad et al.
2011). The original sample was composed by 2294
patients with cancer pain who were ≥18 year of age, had
regular opioid treatment for at least 3 days for moderate
or severe pain and able to speak the language used at the
study center. In this study, we selected those with avail-
able genetic data and cognitive assessment by Mini-Men-
tal State Examination (MMSE).
Research protocol was approved by local ethics com-
mittees (Regional Medical Research Ethics Committee,
Central Norway Health Authority, Protocol reference
number: 119-03, approved 27.09.03) and conducted in
accordance with ethical standards of the Declaration of
Helsinki. Written informed consent was obtained from all
patients prior to their inclusion in the study.
Genotyping procedures
Blood samples were collected from the patients, handled,
and stored in each center according to the study protocol,
before shipment to the Department of Laboratory Medi-
cine, Children’s and Women’s Health, Faculty of Medi-
cine, Norwegian University of Science and Technology,
where the genotyping analyses took place. DNA was
extracted from EDTA-blood using the Gentra Puregene
blood kit (Qiagen Science, Germantown, MD). Genotyp-
ing was performed by the SNPlex Genotyping System
according to the supplier’s dry DNA protocol (Applied
Biosystems, Foster City, CA). Capillary electrophoresis
was carried out on an ABI 3730 48-capillary DNA ana-
lyzer (Applied Biosystems). SNPlex signals were analyzed
using the Gene Mapper v.4.0 software (Applied Biosys-
tems) followed by manual reading. Samples with signals
that could not be discriminated from those of negative
controls were excluded and treated as missing data. Two
SNPs, rs4680 and rs1045642, were genotyped by TaqMan
SNP allelic discrimination analysis, using an ABI 7900HT
analyzer (Applied Biosystems).
In this study, selection of candidate genes and SNPs
was restricted to a previous pool of genes analyzed
regarding genetic variations and morphine efficacy (Klep-
stad et al. 2011). Those genes in the pool that according
to the literature had any relation to cognitive function
were selected for the present analyses.
Cognitive function assessment
Mini-Mental State Examination is an observer-rated brief
battery of simple cognitive tests, which measure orienta-
tion to time and place, registration of words, attention,
calculation, word recall, language, and visual construction.
Scores range from 0 to 30. The cutoff between scores 26
and 24 means possible cognitive dysfunction and below
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24 definite cognitive dysfunction (Folstein et al. 1984;
Crum et al. 1993; Kurita et al. 2011).
Analyses
Statistical analyses were performed based on four steps:
1 The candidate SNPs were rejected if there was evidence
of violation of Hardy–Weinberg equilibrium, which in
the present data set was calculated as the difference
between the observed and expected frequencies being
P < 0.0005. They were also rejected if the minor allele
frequency was <5%.
2 Patients were randomly divided into discovery sample
for initial SNPs screening (discovery phase: 2/3
patients) and the validation sample for confirmatory
test (replication phase: 1/3 patients). In order to con-
firm that SNPs is associated with cognitive function,
the significant results found in the discovery sample
should be replicated in the validation sample.
3 A false discovery rate of 10% was used for determining
associations (Benjamini–Hochberg method), in which
10% of the positive results were expected to be false
positives (Benjamini and Hochberg 1995).
4 The model chosen for the primary genetic analysis was
the co-dominant model and associations were analyzed
considering MMSE scores as a continuous variable and
applying Kruskal–Wallis test. Secondary analyses were
performed using dominant and recessive models, in
which Mann–Whitney test was used. In addition, opi-
oid daily doses were converted to equipotent mg of
oral morphine as described in a previous study (Kurita
et al. 2011) and further analyses were performed con-
sidering only patients receiving ≥400 mg morphine
equivalent dose/day due to the fact that association
between cognitive dysfunction and opioid dose at this
level was observed (Kurita et al. 2011). P-values below
0.05 were considered significant.
Results
Sample characteristics
A total of 1586 patients were analyzed. However, patients
with missing MMSE scores were excluded (n = 217).
Most of them were patients from Norway (24.0%), Italy
(19.9%), Germany (17.4%), and United Kingdom
(17.2%). There were equal proportions of men (50.1%)
and women (49.9%) and the majority were between 50
and 79 years old (76.5%). Approximately 80% of the
sample was composed of inpatients, 23.8% were being
treated with ≥400 mg morphine equivalent dose/day and
27.6% had possible or definite cognitive dysfunction
(Table 1).
Candidate genes
Forty-one candidate genes and 113 SNPs were analyzed.
Out of them, six genes were excluded because they vio-
lated Hardy–Weinberg equilibrium or the minor allele
presented a very low frequency. In addition, SNPs with
more than 25% missing values were excluded from all
analyses. Finally, 83 SNPs in 35 genes were analyzed in
1369 patients (Table 2).
Co-dominant model: Significant associations were
observed between MMSE scores and the SNPs HTR3E
rs6443950 (P = 0.003), TACR1 rs881 (P = 0.006), and
IL6 rs2069835 (P = 0.019) in the discovery sample, but
the replication in the validation sample did not con-
firm the associations (Table 3). When only patients
receiving ≥400 mg morphine equivalent dose/day
(n = 300) were analyzed, significant associations
between MMSE scores and SNPs TNFRSF1B rs3397,
TLR5 rs5744168, HTR2A rs6311, and ADRA2A
rs11195419 were observed in the discovery sample, but
did not reach significance in the validation sample
(Table 4). After correction for multiple testing, no
SNPs were significant in the discovery sample.
Dominant model: Three significant associations were
observed between MMSE scores and SNPs in the dis-
covery sample (HTR3E rs6443950, IL6 rs2069835, and
HTR2A rs6311), but the replication in the validation
sample did not confirm the associations (Table 3). In
patients receiving ≥400 mg morphine equivalent dose/-
day, there were five significant SNPs in the discovery
sample (TACR1 rs2160652, HTR2A rs6311, TLR5
rs5744168, ADRA2A rs11195419, TNFRSF1B rs3397),
but none of them was significant in the validation
sample (Table 4). After correction for multiple testing,
no SNPs were significant in the discovery sample.
Recessive model: Three significant associations were
observed between MMSE scores and SNPs in the dis-
covery sample (TGFB2 rs1418553, GABBR2 rs2304389,
TACR1 rs881), but the replication in the validation
sample did not confirm the associations (Table 3). In
patients receiving ≥400 mg morphine equivalent dose/-
day, there four significant SNPs in the discovery sam-
ple (GABBR2 rs2779562, HTR3E rs6443950, IL6
rs2069835, ADRA2A rs553668), but none of them was
significant in the validation sample (Table 4). After
correction for multiple testing, no SNPs were signifi-
cant in the discovery sample.
Discussion
In this study, a thorough exploration of 83 SNPs in 35
genes related to cognitive function was performed using
ª 2016 The Authors. Brain and Behavior published by Wiley Periodicals, Inc. Brain and Behavior, doi: 10.1002/brb3.471 (3 of 14)
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three current well-accepted genetic models (dominant,
co-dominant and recessive) with discovery (discovery
sample) and replication (validation sample) analyses (Let-
tre et al. 2007). Associations between SNPs and cognitive
function in the total sample were explored, as well as
considering that opioid can interfere on cognitive func-
tion, an analysis of SNPs and cognitive function in those
patients receiving ≥400 mg morphine equivalent dose/day
was also performed. Although some SNPs were associated
with cognitive function in the discovery analysis, the
replication did not confirm any associations.
The absence of associations in this study may be due to
one or more of the following possibilities: (1) the candi-
date genes of this study do not interfere with cognitive
function; (2) cognitive dysfunction is influenced by poly-
genic genetic variations instead of isolated SNPs; (3)
study limitations including influence of other variables
(e.g., medication, comorbidities, general comprehensive
measure of cognitive assessment as opposed to several
instruments that investigate different specific domains),
predefined genes, analysis of different opioids converted
as morphine equivalents, and small sample size.
Targeting the correct genes and analysis
approach
The genetic variability and associations with cognitive
function is better described in the literature when focus-
ing on specific mental diseases, in which there is a more
straightforward identification of impairment and a direct
relationship between genetic alteration (usually a muta-
tion) and phenotype. The effect size of common SNPs is
generally low and the majority is located in noncoding
regions. Any effect from SNPs outside coding regions
may be due to linkage disequilibrium with other func-
tional SNPs with higher effect size, but very often at
much lower frequency (Edwards et al. 2013).
Moreover, the selection of the analysis methods seems
to play a fundamental role. The investigation of genetic
Table 1. Patient’s characteristics (n = 1586).
Characteristics n %
Country of residence
Denmark 19 1.2
Finland 22 1.4
Germany 276 17.4
Greece 3 0.2
Iceland 108 6.8
Italy 316 19.9
Lithuania 35 2.2
Norway 380 24.0
Sweden 91 5.7
Switzerland 64 4.0
United Kingdom 272 17.2
Gender
Men 795 50.1
Women 791 49.9
Age
18–39 year 76 4.8
40–49 year 185 11.7
50–59 year 352 22.2
60–69 year 491 31.0
70–79 year 371 23.4
≥80 year 110 6.9
No information 1 0.1
Settings
Palliative care unit /Hospice 535 33.7
General oncology ward 645 40.7
Surgical ward 59 3.7
Outpatient clinic 347 21.9
Cancer type
GI 300 18.9
Lung 233 14.7
Breast 214 13.5
Prostate 172 10.8
Female reproductive organs 113 7.1
Urologic 103 6.5
Hematologic 94 5.9
Head and neck 62 3.9
Sarcoma 41 2.6
Pancreatic 32 2.0
Skin 25 1.6
Other or more than one type 197 12.4
Metastasis CNS
Yes 97 6.1
No 1489 93.9
Karnofsky performance
Able to carry on normal activity/work 343 21.6
Unable to work 932 58.8
Unable to care for self 308 19.4
No information 3 0.2
Type of opioid
Morphine only 610 38.5
Fentanyl only 405 25.5
Oxycodone only 272 17.2
Hydromorphone only 54 3.4
Buprenorphine 36 2.3
(Continued)
Table 1. Continued.
Characteristics n %
Methadone 30 1.9
Other or combination of opioids 178 11.2
No information 1 0.1
Opioid mg/day (morphine eq.)
<400 1209 76.2
≥400 377 23.8
Mini Mental State Examination score
≤26 437 27.6
>26 932 58.8
No information 217 13.6
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variability in the phenotype of interest is usually based on
two approaches. In the first approach, a selected number
of genetic variations are tested for single associations
founded in hypotheses regarding biological functions of
candidate genes (candidate gene design). In the second,
many random SNPs are tested for associations with
phenotype under a statistical correction for multiple
hypotheses testing based on the proposition that cognitive
traits are controlled by multiple genes (genome-wide
association study) (Rietveld et al. 2014). Until now, these
approaches on cognitive function have failed to replicate
findings or have found small significant associations
(Chabris et al. 2012; Payton 2009; Davies et al. 2011;
Benyamin et al. 2014).
In the candidate gene design, most effects of genes on
cognitive processing are often analyzed by methods of
genetic linkage and association, which result in a statisti-
cal modeling that examines relations between a part of
the chromosome and a phenotype (Flint 1999). However,
it has been suggested that cognitive impairment does not
result from a mutation in a single gene and that varia-
tions regarding intelligence quotients involve combina-
tions of a number of genes (polygenic genetic basis) that
influence, for example, impairment (Nokelainen and Flint
2002). Thus, genome-wide studies have demonstrated the
influence of polygenic variations on cognitive function,
psychiatric diseases, and dementing processes (Bulayeva
et al. 2015).
Meta-analysis of population cohorts is another
approach in the genome-wide studies, which can include
polygenic analyses. However, the studies showed that the
SNPs assessed have accounted for a very small portion
(2%) of the phenotypic variance (Rietveld et al. 2013;
Davies et al. 2015). Other methods to refine genetic anal-
ysis include analysis of subgroups with common charac-
teristics pertinent to specific diseases (Debette et al.
2015). Therefore, the genome-wide studies have indicated
that cognitive dysfunction may result from combination
of genetic variants rather than individual effect of a SNP.
However, combination of genetic variants often requires
large samples in order to successfully replicate findings,
estimate predictors by polygenic analyses (Dudbridge
2013), and identify 1–2% of genetic variability. It is a
notion for power calculation and estimates of the possible
effect sizes of future studies.
Candidate genes for opioid effects and
consequences for cognitive function
Previous knowledge on the association between high opioid
doses and cognitive dysfunction (Kurita et al. 2011), and a
possible connection with genes that may have influence on
Table 3. SNPs associated with MMSE scores (n = 1369).
Gene SNP Minor allele
Discovery sample (n = 911)
P
Validation sample (n = 458)
P
Genotype
frequency
MMSE score
(median)
Genotype
frequency
MMSE score
(median)
Co-dominant
HTR3E rs6443950 A AA AT TT AA AT TT 0.003 AA AT TT AA AT TT 0.715
111 402 361 27 28 28 49 227 167 28 28 28
CC CG GG CC CG GG CC CG GG CC CG GG
TACR1 rs881 C 28 244 607 28.5 28 28 0.006 19 122 304 27 28 28 0.911
CC CT TT CC CT TT CC CT TT CC CT TT
IL6 rs2069835 C 6 103 708 30 28 28 0.019 3 52 354 29 28 27.5 0.472
Dominant
HTR3E rs6443950 A AA+AT TT AA+AT TT 0.003 AA+AT TT AA+AT TT 0.658
763 111 28 27 276 167 28 28
TT+CT CC TT+CT CC TT+CT CC TT+CT CC
IL6 rs2069835 C 811 6 28 30 0.006 55 354 28 28 0.450
TT+CT CC TT+CT CC TT+CT CC TT+CT CC
HTR2A rs6311 T 601 273 28 28 0.019 291 151 28 28 0.594
Recessive
TGFB2 rs1418553 T CC+CT TT CC+CT TT 0.020 CC+CT TT CC+CT TT 0.666
765 83 28 27 397 34 28 28.5
GG+AG AA GG+AG AA GG+AG AA GG+AG AA
GABBR2 rs2304389 A 243 613 28 28 0.035 410 20 28 29 0.630
CG+GG CC CG+GG CC CG+GG CC CG+GG CC
TACR1 rs881 C 272 607 28 28 0.041 426 19 28 27 0.486
SNP, Single-nucleotide polymorphisms; MMSE, Mini-Mental State Examination.
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opioid effects (Somogyi et al. 2007; Klepstad 2010; Barratt
et al. 2014) prompted us to analyze a subgroup of patients
receiving high opioid doses. We expected that associations
between cognitive dysfunction and SNPs in genes of
patients treated with morphine equivalent doses ≥400 mg/
day could be found; however, that proved not to be the
case. A too small sample size based on a reduced number of
patients on high opioid doses may have played a role for
the negative outcomes. It is interesting to note that a for-
mer study regarding opioid efficacy in the total sample of
opioid-treated patients in the EPOS study did not show sig-
nificant associations between genetic variability and opioid
dosage (Klepstad et al. 2011).
Strengths and limitations
Strengths of this study include large sample size, diversity
of included patients with cancer on opioid treatment,
investigation of genes that were reported by the literature
to have some relationship with cognitive function, and
robust methods of analysis involving three genetic models
and removal of false positives. On the other hand, several
factors may have hampered the identification of genetic
variability related to cognitive function. First, the mecha-
nisms influencing cognitive function are complex and
many variables such as medication, psychiatric/psycholog-
ical disorders, and disease may influence the performance
on different neuropsychological tests not related to
genetic variation (Kendler and Neale 2010). Second, there
exist several neuropsychological tests to assess different
cognitive domains and consensus regarding the best
instrument for each domain in this particular population
is still under development. In this study MMSE was
selected due to brevity and easy application, extensive use
in research and clinical practice (Folstein et al. 1984;
Crum et al. 1993), and its status as the “golden standard”
instrument to measure cognitive function in patients with
cancer (Meyers and Wefel 2003). However, criticism of
MMSE includes rough measurement properties of cogni-
tion and psychometric limitations in nondemented popu-
Table 4. SNPs associated with MMSE score among patients receiving daily oral morphine equivalent doses of 400 mg or more (n = 300).
Gene SNP Minor allele
Discovery sample (n = 202)
P
Validation sample (n = 98)
P
Genotype
frequency
MMSE score
(median)
Genotype
frequency
MMSE score
(median)
Co-dominant
TNFRSF1B rs3397 C CC CT TT CC CT TT 0.014 CC CT TT CC CT TT 0.118
31 85 75 27 26 28 10 34 50 23.5 28 28.5
TC CT TT TC CT TT TC CT TT TC CT TT
TLR5 rs5744168 T 179 16 0 27 25 – 0.020 82 10 2 28 26.5 29.5 0.332
CC CT TT CC CT TT CC CT TT CC CT TT
HTR2A rs6311 T 61 103 31 28 26 27 0.032 29 49 18 27 28 28 0.598
AA AC CC AA AC CC AA AC CC AA AC CC
ADRA2A rs11195419 A 2 44 133 27.5 28 27 0.039 2 26 65 28 28 28 0.930
Dominant
TACR1 rs2160652 T TT+GT GG TT+GT GG 0.040 TT+GT GG TT+GT GG 0.523
106 92 28 26 50 46 28 28
TT+CT CC TT+CT CC TT+CT CC TT+CT CC
HTR2A rs6311 T 134 61 27 28 0.024 67 29 28 27 0.455
TT+CT CC TT+CT CC TT+CT CC TT+CT CC
TLR5 rs5744168 T 16 179 25 27 0.020 12 82 28.5 28 0.982
AA+AC CC AA+AC CC AA+AC CC AA+AC CC
ADRA2A rs11195419 A 46 133 28 27 0.011 28 65 28 28 0.816
CC+CT TT CC+CT TT CC+CT TT CC+CT TT
TNFRSF1B rs3397 C 116 75 26.5 28 0.005 44 50 28 28.5 0.159
Recessive
GABBR2 rs2779562 T CC+CT TT CC+CT TT 0.038 CC+CT TT CC+CT TT 0.656
141 52 27 28 67 28 28 28
AT+TT AA AT+TT AA AT+TT AA AT+TT AA
HTR3E rs6443950 A 176 23 27 25 0.034 89 278 28 28.5 0.652
CC+CT TT CC+CT TT CC+CT TT CC+CT TT
IL6 rs2069835 T 189 2 27 30 0.029 91 1 28 30 0.188
CC+CT TT CC+CT TT CC+CT TT CC+CT TT
ADRA2A rs553668 T 140 5 28 23 0.022 67 2 28 27 0.731
SNP, Single-nucleotide polymorphisms; MMSE, Mini-Mental State Examination.
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lations. The main instrument weaknesses are lack of sensi-
tiveness to detect milder alterations, no contemplation of
other important cognitive domains (e.g., executive func-
tion), potential learning effect, and influence of other
variables as age, schooling, and social background on the
score (Spencer et al. 2013). Third, the genes were selected
from a pre-established pool, which did not necessarily
encompass all genes potentially associated with cognitive
function as APOE, which is associated to Alzheimer’s dis-
ease and cognitive decline in older age (Ertekin-Taner
2007; Christensen et al. 2008). Fourth, the different opi-
oids were converted to doses of morphine equivalents in
order to allow us to work with a larger sample; however,
there is a possibility that each distinct type of opioid
(e.g., morphine, oxycodone, fentanyl, and methadone)
has a specific interference with cognitive functioning.
Fifth, in spite of the large number of patients in the sam-
ple, it may not have been large enough to identify signifi-
cant associations, especially if compared to the modest
findings in genome-wide studies with larger samples.
Although our candidate gene approach does not capture
all genes and genetic variants that are relevant for cogni-
tive function, applying a genome-wide association
approach was not a realistic option for our study because
of the limited sample size and the high threshold for
reaching the genome-wide level of statistical significance.
Moreover, the validation sample was smaller than the dis-
covery sample, disregarding any overestimation of effect
size (Bush and Moore 2012). The same rationale applies
even more pronounced to the analysis of SNPs in patients
on high opioid doses (≥400 mg morphine equivalent
dose/day) that may also be hampered by the small num-
ber of individuals in this subgroup. The effect size of phe-
notypic characteristics is usually small, which requires
analysis of even larger sample sizes (Debette et al. 2015).
Nevertheless, small effect size characterizes the veracity of
common genetic variability (Edwards et al. 2013).
This study focused on the effects of SNPs on cognitive
function of opioid-treated patients with cancer, and since
factors as socio-demographics, comorbidities, and treat-
ments, among others have been previously explored (Kur-
ita et al. 2011, 2015), they were not reanalyzed. We did
not discard the possibility of other variables to interfere
with cognitive functioning and overlap genetic interfer-
ence potentializing the effects or overshadow genetic
interference. Prevalent determinants in cancer as aging
and inflammation may play an import role. Inflammatory
biomarkers have been identified in several neurological
diseases (e.g., Parkinson and dementias) and in acute
infections, which have been associated with declined cog-
nitive performance (Simen et al. 2011). Also, investigation
of inflammatory biomarker levels in African Americans
and Caucasians have suggested associations between IL-8,
cognitive function and ethnic background (Goldstein
et al. 2014). Moreover, protective measures as intake of
nonsteroidal anti-inflammatory drugs seem to slow down
development of neurological diseases as Alzheimer’s dis-
ease and prevent cognitive decline in subjects with
apolipoprotein E (APOE) e4 alleles (Hayden et al. 2007;
Gorelick 2010).
Therefore, suggestions for future research in this area
should consider the multifactorial nature of cognitive dys-
function and a proper study design. A better understanding
of the issue, besides involving genetic aspects (exploration
of other sets of genes, combined genes effects, mRNA levels,
and polygenic analyses), should also consider several other
variables related to cancer. The variety of potential causes
for cognitive dysfunction includes known variables in the
cancer population (e.g., socio-demographics, comorbidi-
ties, treatment, etc.), information from other conditions
(e.g., inflammation biomarkers, dementia structural brain
changes, neurodegeneration in older age, etc.), and vari-
ables not explored, but involving a plausible hypothesis
(e.g., genes analyzed in animal studies). In addition, larger
cohorts with adequate sample size and better methods of
cognitive assessment are essential to provide high-quality
data and possible definite answers.
In conclusion, the findings of this study did not sup-
port influence of those SNPs analyzed to explain cognitive
dysfunction in this sample of patients. Several factors may
have played a role blurring the potential identification of
significant associations. Nonetheless, to the best of our
knowledge, this is the first study to explore genetic vari-
ability and cognitive dysfunction in opioid-treated
patients with cancer. Larger multicenter collaboration and
interest of funding institutions are highly required for
further investigation.
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